![](images/null.gif) |
|
Ryan White Care Hepatitis C & B Language
|
NATAP Webinars
|
|
Hepatitis C: Update on Test & Treat Models, Women & Pregnancy
Friday, June 14th, 2024 - 12:30pm
Click To Register:
Hepatitis C: Update on Test & Treat Models, Women & Pregnancy
|
View all archived NATAP webinars here
|
![icon star paper](images/icons/icon_star_paper.gif) |
Current HIV Articles and News Updates |
![](images/null.gif) |
|
|
|
![](images/null.gif) |
- CROI:
31st Conference on Retroviruses and Opportunistic Infection
Eric S. Daar, M.D.
- Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA - (03/26/24)
 
More HIV Articles...
|
![](images/null.gif) |
|
|
|
![](images/null.gif) |
- HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines
 
- EASL: Robust reduction of HBsAg and HDV RNA levels with low risk for ALT elevations in JNJ-73763989 treated patients with chronic hepatitis D (CHD) and baseline HBsAg levels below 10,000 IU/mL: Part 2 of the REEF-D study
- (06/18/24)
 
- EASL: Pharmacokinetics and Safety of Single Dose of the Monoclonal Antibody Tobevibart (VIR-3434) Administered as Monotherapy or in Combination with the Small Interfering RNA Elebsiran (VIR-2218) in Cirrhotic Participants with Mild Hepatic Impairment
- (06/18/24)
 
- EASL HDV infection in Israel: Epidemiology and co-morbidities
- (06/18/24)
 
- EASL Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: preliminary results from the phase 2 SOLSTICE trial in non-cirrhotic and compensated cirrhotic participants
- (06/18/24)
 
- EASL: Bulevirtide in combination with pegylated interferon alfa-2a shows a sustained off-treatment response in the liver - (06/08/24)
 
- EASL The burden of chronic hepatitis delta in Italy: potential impacts and effects of bulevirtide through Cost of Illness and Cost Consequence Analysis
- (06/14/24)
 
- EASL Healthcare Resource Utilisation and Costs of Hepatitis Delta Virus Infection vs Hepatitis B Virus Monoinfection Across Disease States Among Hospitalised Adults in Italy
- (06/14/24)
 
- EASL Bulevirtide Monotherapy Lowers Risk of Decompensation But Not HCC
- Mark Mascolini (06/14/24)
 
- EASL The underestimated burden of hepatitis D among people living with chronic hepatitis B in the Gambia
- (06/14/24)
 
- EASL
Tobevibart (VIR-3434), a Monoclonal Antibody, Resistance Analysis in Participants With Chronic HBV: Results From a Phase 1, Single-dose Study
- (06/14/24)
 
- EASL Pharmacokinetics and Safety of Single Dose of the Monoclonal Antibody Tobevibart (VIR-3434) Administered as Monotherapy or in Combination with the Small Interfering RNA Elebsiran (VIR-2218) in Cirrhotic Participants with Mild Hepatic Impairment
- (06/14/24)
 
- EASL Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: preliminary results from the phase 2 SOLSTICE trial in non-cirrhotic and compensated cirrhotic participants
- (06/14/24)
 
- EASL
Pre- and Post-Bulevirtide Biopsies Show HDV RNA Drops in Liver Track With Drops in Blood
- (06/13/24)
 
- EASL Pre- and Post-Bulevirtide Biopsies Show HDV RNA Drops in Liver Track With Drops in Blood
- Mark Mascolini (06/13/24)
 
- EASL Preclinical Profiling of ABI-6250, a Novel Orally Bioavailable Small-Molecule Therapeutic Candidate for the Treatment of Chronic Hepatitis
- (06/13/24)
 
- EASL No Amino Acid Substitution in HBV Pres1, HDAg, Or NTCP Associated With Suboptimal Response to Bulevirtide in Combination With Pegylated Interferon Alfa-2a Treatment in Participants With Chronic Hepatitis Delta: Results From MYR204, a Phase 2b Study
- (06/13/24)
 
- EASL Efficacy and Safety of 144 Weeks of Bulevirtide 2 mg or
10 mg Monotherapy From the Ongoing Phase 3 Study MYR301
- (06/13/24)
 
- EASL Bulevirtide monotherapy prevents liver decompensation and reduces mortality in patients with HDV-related cirrhosis: a case control study with propensity score weighted analysis
- (06/13/24)
 
- EASL
LONG-TERM VIROLOGICAL AND CLINICAL OUTCOMES OF PATIENTS WITH HDV-RELATED CIRRHOSIS TREATED WITH BULEVIRTIDE MONOTHERAPY FOR UP TO 120 WEEKS: A RETROSPECTIVE MULTICENTER EUROPEAN STUDY (SAVE-D)
- (06/13/24)
 
- EASL
Sustained virological response after treatment with Bulevirtide in HDV patients. Data from the french multicenter real-life cohort
- (06/13/24)
 
- EASL
Bulevirtide in combination with pegylated interferon alfa-2a
shows a sustained off-treatment response in the liver
- (06/13/24)
 
- EASL
Unique Characteristics and Risk of Liver-Related Events Among Individuals With Hepatitis Delta Virus Infection With and Without Concurrent Hepatitis C Virus Infection: A United States Administrative Claims Data Analysis
- (06/13/24)
 
- EASL
Anti-HDV and HDV RNA Testing Rates for Hepatitis Delta Virus Among Adult Patients in the United States
- (06/13/24)
 
- EASL
Bulevirtide efficacy and safety in chronic hepatitis D patients on liver transplant waiting list for decompensated cirrhosis and/or hepatocellular carcinoma
- (06/13/24)
 
- EASL High frequency of liver cirrhosis in European patients with hepatitis D: First data from a large multicentre study (D-SOLVE and HDV-1000 consortia)
- (06/13/24)
 
- EASL Rapid Reductions of HDV RNA and ALT with the Monoclonal Antibody, BJT-778: Results from a Phase 2 Study
- (06/13/24)
 
- EASL Rapid Reductions of HDV RNA and ALT with the Monoclonal Antibody, BJT-778: Results from a Phase 2 Study
- (06/12/24)
 
- EASL Safety and efficacy of REP 2139-Mg in hepatitis D patients with advanced liver disease: an international compassionate use program
- (06/12/24)
 
- EASL Undetectable HDV RNA Defined as Target Not Detected at the End of Treatment With Bulevirtide and/or Pegylated Interferon Alpha-2a Is an Important Predictor of 48 Weeks Sustained Virologic Response in Chronic Hepatitis Delta
- (06/12/24)
 
- EASL
Bulevirtide Plus pegIFNα Superior
to Bulevirtide Alone for Chronic HDV
- Mark Mascolini (06/12/24)
 
- EASL Undetectable HDV RNA at 24 Weeks of Treatment With Bulevirtide and Pegylated Interferon Alfa-2a Combination Therapy Is an Important Predictor of Maintained Response Off-Therapy
- (06/12/24)
 
- EASL
Impact of Bulevirtide Given With or Without Nucleos(t)ide Analogues
on 48-Week Virologic Outcomes in Patients With Chronic Hepatitis Delta Virus Infection
- (06/12/24)
 
- EASL Improvement in Liver Histology Is Observed in Most Patients With
Chronic Hepatitis Delta After 48 Weeks of Bulevirtide Monotherapy
- (06/11/24)
 
- EASL Bulevirtide Plus pegIFNα
Superior to Bulevirtide Alone for Chronic HDV
- Mark Mascolini (06/11/24)
 
- EASL Hepatitis Delta Virus Infection is Associated with Significantly Greater Incidence of Cirrhosis and Hepatic Decompensation in U.S. Veterans with Chronic Hepatitis B
- (06/11/24)
 
- EASL
Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D
- (06/11/24)
 
- EASL
48-Week Off-Therapy Efficacy and Safety of Bulevirtide in Combination with Pegylated Interferon Alfa-2a in Patients with Chronic Hepatitis Delta: Final Results from the Phase 2b, Open-Label, Randomised, Multicentre Study MYR204
- (06/11/24)
 
More Hep D Articles...
 
 
-
Food Is Medicine for Human Immunodeficiency Virus: Improved Health and Hospitalizations in the Changing Health Through Food Support (CHEFS-HIV) Pragmatic Randomized Trial - (06/21/24)
 
- Dasatinib + Quercetin Drugs Reduced Senescent-Associated Secretory Phenotype (SASP) in PLWH PBMCs - (06/21/24)
 
- Age-associated dementia (30%) among older people aging with HIV in the United States: a modeling study - (05/24/24)
 
-
Comparison of dementia risk after age 50 between individuals with and without HIV infection: 58% Higher Risk, 10 years Earlier - (05/24/24)
 
- CROI: EPIGENETIC IMPACT IN CSF CELLS FROM 48 WEEKS OF ADJUNCTIVE TELMISARTAN IN ACUTE HIV - (04/15/24)
 
More Aging & HIV Articles...
 
 
- The relationship between anti-LGBTQ+ legislation and HIV prevention among sexual and gender minoritized youth - (05/23/24)
 
- Impact of HIV pre-exposure prophylaxis prescriptions on HIV diagnoses in New York city: disparities in new HIV diagnosis - (05/23/24)
 
- Feasibility of Implementing a Low-Barrier Long-Acting Injectable Antiretroviral Program for HIV Treatment & Prevention for People Experiencing Homelessness - (04/03/24)
 
More PreP Articles...
|
![](images/null.gif) |
| |
![](images/null.gif) |
![](images/null.gif) |
|
|
![null.gif](images/null.gif) |
|
![icon paper stack](images/icons/icon_paper_stack.gif) |
Current Hepatitis C and B Articles |
![](images/null.gif) |
|
|
|
![](images/null.gif) |
|
![](images/null.gif) |
|
![](images/null.gif) |
|
|
|
![](images/null.gif) |
- HBV Patient Declaration of Rights -
 
- EASL: Evaluating the effectiveness and safety of tenofovir alafenamide fumarate for preventing mother to child transmission of hepatitis B virus - (06/18/24)
 
- EASL: Efficacy and safety of tenofovir alafenamide fumarate in preventing HBV vertical transmission in high maternal viral load: a multi-centre, prospective cohort study - (06/18/24)
 
- EASL: Off-treatment Outcomes After Discontinuing Tenofovir-based Treatment in Hepatitis B e Antigen-positive and Hepatitis B e Antigen-negative Patients With Chronic Hepatitis B Virus
- (06/18/24)
 
- EASL: Extended Treatment of HBeAg+ CHB Subjects with the Capsid Assembly Modulator ALG-000184 with or without Entecavir is Associated with Reductions in Viral Markers and Favorable Anti-HBeAg trends - (06/18/24)
 
- EASL: Safety and antiviral activity of AHB-137, a novel antisense oligonucleotide,
in healthy volunteers and subjects with chronic hepatitis B - (06/18/24)
 
- EASL: Multinational randomized trial to investigate the efficacy of tenofovir alafenamide in reducing adverse clinical events in chronic hepatitis B patients who are beyond treatment indications by current guidelines (ATTENTION trial): first interim analysis
TAF Slices Serious Liver Outcomes 80% in People Without High ALT - Mark Mascolini (06/18/24)
 
- EASL: Association Between Post-treatment ALT Elevation and Subsequent HBsAg Seroclearance in Chronic Hepatitis B Patients Stopping NUC Therapy - (06/18/24)
 
- EASL: Hepatic flares after nucleos (t)ide analogue cessation in HBeAg
negative hepatitis B: results from the Nuc-Stop study
- (06/17/24)
 
- EASL: Progression and risk factors after treatment with tenofovir
or entecavir for chronic hepatitis B based on a multistate modeling approach
- (06/17/24)
 
- EASL: Evaluation of a novel HBV DNA test from fingerstick capillary
blood at the point-of-care as a tool to enhance clinical management
- (06/17/24)
 
- EASL: Efficacy, safety, tolerability, and immunogenicity of JNJ-0535 following a reduction of viral antigen levels through administration of siRNA JNJ-3989 in patients with chronic HBeAg negative hepatitis B - interim data of the OSPREY study
- (06/17/24)
 
- EASL: VTP-300 immunotherapeutic, plus low dose PD-1 inhibitor,
nivolumab, continues to show meaningful, sustained reductions in HBsAg levels
- (06/17/24)
 
- EASL: Imdusiran (AB-729) administered every 8 weeks for 24 weeks followed by the immunotherapeutic VTP-300 maintains lower HBV surface antigen levels in NA-suppressed CHB subjects than 24 weeks of imdusiran alone
- (06/17/24)
 
- EASL: Tobevibart (VIR-3434), a Monoclonal Antibody, Resistance Analysis in Participants With Chronic HBV: Results From a Phase 1, Single-dose Study
- (06/17/24)
 
- EASL:
Therapeutic Vaccine (BRII-179 Plus siRNA (BRII-835) Stir T-Cell Response Tied to Lower HBsAg
- Mark Mascolini (06/17/24)
 
- EASL:
Tenofovir-Based HBV Treatment Cuts HCC Risk After Several Years
- Mark Mascolini (06/17/24)
 
- EASL:
Long-term hepatitis B surface antigen response after finite treatment with siRNAs ARC-520 or JNJ-3989
- (06/17/24)
 
- EASL:
Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
- (06/17/24)
 
- EASL: Tenofovir disoproxil fumarate and tenofovir alafenamide interruption in hepatitis B and human immunodeficiency virus co-infected individuals in the United States: monitoring practices and incidence of hepatitis B reactivation or hepatitis flare
- (06/12/24)
 
More Hep B Articles...
 
 
- EASL: Identification and validation of pre-identified morphological
baseline features for prediction of fibrosis progression in MAESTRO-NASH - (06/18/24)
 
- EASL: Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis
- (06/12/24)
 
- EASL: Development and Validation of CLDQ-MASH: A Disease-specific Health-related Quality of Life Instrument for Patients with MASH
- (06/12/24)
 
- EASL: Results from a phase 2a randomized trial with the transglutaminase 2 inhibitor ZED1227 in patients with MASLD
- (06/12/24)
 
- EASL: Week 48 results from the phase 2b ENLIVEN extension study investigating pegozafermin for the treatment of metabolic dysfunction-associated steatohepatitis with fibrosis
- (06/12/24)
 
- EASL: Denifanstat, a fatty acid synthase (FASN) inhibitor, shows significant
fibrosis improvement and MASH resolution in FASCINATE-2, a Ph2b 52 week
international, randomized, double blind, placebo-controlled trial
in patients with F2 or F3 fibrosis
- (06/12/24)
 
- EASL:
The economic burden of MASLD and MASH in US, Japan, Germany......$300 billion+, $62 B direct healthcare costs, $250 billion productivity loss in USA
- (06/12/24)
 
- EASL:
Tirzepatide for the treatment of metabolic dysfunction-associated
steatohepatitis with liver fibrosis: results of the SYNERGY-NASH phase 2 trial
- (06/12/24)
 
- EASL: Structured exercise plus mediterranean diet intervention in patients with metabolic-dysfunction associated steatotic liver disease (MASLD): a randomized controlled trial. The EHmet-DIA study
- (06/12/24)
 
- EASL: Assessment of resmetirom efficacy (80 mg vs. 100 mg) stratified by baseline body mass index and weight in patients from the MAESTRO-NASH trial
- (06/12/24)
 
- EASL:
Survodutide (BI 456906), a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, in people with compensated and decompensated cirrhosis: a multinational, open-label, phase 1 trial
- (06/12/24)
 
- EASL:
Characteristics and risk of major adverse liver outcomes and major cardiovascular events among Swedish patients with diagnosed and high risk of metabolic dysfunction-associated steatohepatitis-a REVEAL-MASH study High Fibrotic NASH Index Predicts 20% 10-Year Cardio Event Risk
- Mark Mascolini (06/12/24)
 
- EASL: Prognostic significance of a change in liver stiffness measurement by vibration-controlled transient elastography - a multicenter cohort study of 10,920 patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
- (06/12/24)
 
More Fatty Liver Articles...
|
![](images/null.gif) |
![](images/null.gif) |
|
![](images/null.gif) |
|
|
![](images/null.gif) |
![](images/null.gif) |
| | |